How many Performance Share Units did SUPN’s CEO vest and convert to shares?

Jack A. Khattar exercised 29,849 Performance Share Units into the same number of shares of SUPERNUS PHARMACEUTICALS common stock after a portion of the award vested upon achievement of individual performance objectives set in May 2025.

What indirect SUPN share holdings are reported for Jack A. Khattar?

The Form 4 shows 958,100 shares of SUPERNUS common stock held indirectly "By the KBT Trust". This entry reflects indirect ownership through the trust rather than additional directly held shares.

When were the SUPN Performance Share Units granted and what triggered vesting?

The Performance Share Units were awarded on February 19, 2025, with a portion vesting upon achievement of individual performance objectives that were established on May 3, 2025, as described in the filing’s footnotes.

Supernus CEO exercises 29,849 performance share units

Q: What did SUPN CEO Jack A. Khattar report in this Form 4 transaction?

Jack A. Khattar reported exercising 29,849 Performance Share Units into common stock on August 12, 2026, with a portion of the resulting shares withheld to cover tax withholding requirements tied to the vesting of these units.

Q: How many SUPN shares were withheld for taxes in Khattar’s August 2026 transaction?

A total of 12,642 shares of SUPERNUS PHARMACEUTICALS common stock were withheld by the company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units awarded to Jack A. Khattar.

Q: Was Jack A. Khattar’s SUPN transaction made under a Rule 10b5-1 plan?

The Form 4’s Rule 10b5-1 checkbox is not marked as affirming a plan, and there is no footnote stating the trades were pursuant to a pre-arranged Rule 10b5-1 trading plan.

SUPERNUS PHARMACEUTICALS, INC. reported that President and CEO Jack A. Khattar exercised 29,849 Performance Share Units into an equal number of shares of common stock on August 12, 2026.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

SUPERNUS PHARMACEUTICALS, INC. reported that President and CEO Jack A. Khattar exercised 29,849 Performance Share Units into an equal number of shares of common stock on August 12, 2026. Of these shares, 12,642 were withheld to satisfy tax withholding requirements related to the vesting of the Performance Share Units. The remaining shares from this award increased his directly held common stock. A separate line shows 958,100 shares of common stock held indirectly by the KBT Trust. The Performance Share Units were originally awarded on February 19, 2025, and a portion vested upon achievement of individual performance objectives established on May 3, 2025.

Insider Trade Summary

29,849 shares exercised/converted

Exercise 4 txns

Insider Khattar Jack A.

Role President, CEO

Type	Security	Shares	Price	Value
Exercise	Performance Share Unit ^F2	29,849	$0.00	$0.00
Exercise	Common Stock	29,849	$0.00	$0.00
Tax Withholding	Common Stock ^F1	12,642	$46.57	$589K
holding	Common Stock	--	--	--

Holdings After Transaction: Performance Share Unit — 0 contracts (Direct); Common Stock — 1,258,351 shares (Direct); Common Stock — 958,100 shares (Indirect, By the KBT Trust)

Footnotes (2)

F1. Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units.
F2. On February 19, 2025, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on May 3, 2025.

Key Figures

Performance Share Units exercised: 29,849 units Shares withheld for taxes: 12,642 shares Tax withholding price: $46.57 per share +3 more

6 metrics

Performance Share Units exercised 29,849 units Performance Share Units converted into common stock on August 12, 2026

Shares withheld for taxes 12,642 shares Shares of common stock withheld to satisfy tax withholding requirements at $46.57 per share

Tax withholding price $46.57 per share Price used for shares withheld for tax withholding requirements

Indirect holdings by KBT Trust 958,100 shares Common stock held indirectly by the KBT Trust after the reported transactions

PSU award date February 19, 2025 Date the Performance Share Units were awarded to the reporting person

Performance objectives date May 3, 2025 Date individual performance objectives for PSU vesting were established

Key Terms

Performance Share Units, tax withholding requirements, indirect ownership

3 terms

tax withholding requirements financial

"shares of common stock withheld by the Company to satisfy tax withholding requirements"

indirect ownership financial

"Common Stock held indirectly, nature of ownership: By the KBT Trust"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did SUPN CEO Jack A. Khattar report in this Form 4 transaction?

Jack A. Khattar reported exercising 29,849 Performance Share Units into common stock on August 12, 2026, with a portion of the resulting shares withheld to cover tax withholding requirements tied to the vesting of these units.

How many SUPN shares were withheld for taxes in Khattar’s August 2026 transaction?

A total of 12,642 shares of SUPERNUS PHARMACEUTICALS common stock were withheld by the company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units awarded to Jack A. Khattar.

Was Jack A. Khattar’s SUPN transaction made under a Rule 10b5-1 plan?

The Form 4’s Rule 10b5-1 checkbox is not marked as affirming a plan, and there is no footnote stating the trades were pursuant to a pre-arranged Rule 10b5-1 trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 08/14/2026 - 05:13 PM Accepted by SEC EDGAR 08/14/2026 - 05:12 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Khattar Jack A.

(Last)

(First)

(Middle)

C/O SUPERNUS PHARMACEUTICALS INC.

9715 KEY WEST AVENUE

(Street)

ROCKVILLE

MARYLAND

20850

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
SUPERNUS PHARMACEUTICALS, INC. [ SUPN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President, CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	08/12/2026		M		29,849	A	$0	1,270,993	D
Common Stock	08/12/2026		F⁽¹⁾		12,642	D	$46.57	1,258,351	D
Common Stock								958,100	I	By the KBT Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Performance Share Unit	$0	08/12/2026		M			29,849	⁽²⁾	⁽²⁾	Common Stock	29,849	$0	0	D

Explanation of Responses:

1. Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units.

2. On February 19, 2025, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on May 3, 2025.

Remarks:

	/s/ Timothy C. Dec, as attorney-in-fact	08/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR